APOLLO: SLN360 Clears First Major Hurdle, Hammering Lp(a)

The results add to growing enthusiasm for achieving the 'holy grail' of a lipoprotein(a)-specific lowering agent, but whether it will reduce cardiovascular risk remains unknown.
Medscape Medical News

source https://www.medscape.com/viewarticle/971491?src=rss

Comments

Popular posts from this blog

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

New AAFP practice guideline sets blood pressure targets for adults with hypertension